Table 2.
Prevalence of symptoms and incidence of conditions in 31–150 days following SARS-CoV-2 testing among adults and children with positive and negative SARS-CoV-2 test results
| No./total No. (%) | ||||
|---|---|---|---|---|
| Prevalent symptoms and incident conditions | Non-hospitalized | Hospitalized | ||
| Positive | Negative | Positive | Negative | |
| Adults (≥20 years) | ||||
| Symptoms outcomes | ||||
| At least one symptom | 105819/262400 (40.3) | 822370/2020829 (40.7) | 23989/44926 (53.4) | 291712/662295 (44.0) |
| Three or more symptoms | 17946/262400 (6.8) | 148606/2020829 (7.4) | 6843/44926 (15.2) | 73005/662295 (11.0) |
| Fatigue or muscle weakness | 17188/262400 (6.6) | 126156/2020829 (6.2) | 5454/44926 (12.1) | 58508/662295 (8.8) |
| Shortness of breath | 17450/262400 (6.7) | 133948/2020829 (6.6) | 7562/44926 (16.8) | 64494/662295 (9.7) |
| Conditions outcomes | ||||
| Mental health conditions | 14180/188941 (7.5) | 116175/1426799 (8.1) | 3165/30079 (10.5) | 47330/441280 (10.7) |
| Chronic kidney disorders | 2762/252853 (1.1) | 31724/1940517 (1.6) | 1874/35031 (5.3) | 23936/579705 (4.1) |
| Diabetes type 1 or type 2 | 4245/225157 (1.9) | 36944/1778370 (2.1) | 2016/29502 (6.8) | 19753/533887 (3.7) |
| Hematologic disorders | 2248/265308 (0.8) | 18770/2054644 (0.9) | 2082/43284 (4.8) | 18122/646387 (2.8) |
| Major adverse cardiovascular events | 7028/238918 (2.9) | 71936/1783138 (4.0) | 3980/30945 (12.9) | 52227/504033 (10.4) |
| Neurological disorders | 8478/236441 (3.6) | 83539/1791423 (4.7) | 3252/34755 (9.4) | 44248/542090 (8.2) |
| Respiratory diseases | 8298/229162 (3.6) | 73078/1742318 (4.2) | 4463/32125 (13.9) | 37561/527227 (7.1) |
| Children and young adults (0 -19 years) | ||||
| Symptoms outcomes | ||||
| At least one symptom | 15145/58196 (26.0) | 134017/511383 (26.2) | 1196/2725 (43.9) | 32343/91933 (35.2) |
| Three or more symptoms | 1159/58196 (2.0) | 10534/511383 (2.1) | 227/2725 (8.3) | 4841/91933 (5.3) |
| Fatigue or muscle weakness | 1338/58196 (2.3) | 10324/511383 (2.0) | 166/2725 (6.1) | 3674/91933 (4.0) |
| Shortness of breath | 1345/58196 (2.3) | 11730 /511383 (2.3) | 179/2725 (6.6) | 3676 / 91933 (4.0) |
At least one symptom refers to at least one ICD-10 code: fatigue or muscle weakness, shortness of breath, cough, change in bowel habits, abdominal pain, headache, cognitive disorders, disorders of taste and smell, non-cardiac chest pain, heart rate abnormalities, sleep disorders, and myalgia and arthralgia. Three or more symptoms refer to at least 3 ICD-10 diagnosis codes for one or more symptoms. Mental health conditions include anxiety, depression, other mood disorders, overdose, psychosis, substance misuse, and suicide ideation/attempts. Chronic kidney disorders include chronic kidney disease and nephrotic and nephritic syndromes. Hematologic disorders include other venous thromboembolism and pulmonary embolism. Major adverse cardiovascular events include arrythmias, heart failure, intracerebral hemorrhage, ischemic infarction, myocardial infarction, myocarditis, subarachnoid hemorrhage, transient ischemic attack or other stroke. Neurological disorders include ataxia, autonomic dysfunction, dementia, encephalitis, myoneural disorders, parkinsonism, peripheral nerve disorders, and seizures. Respiratory disease includes asthma, chronic bronchitis, chronic obstructive pulmonary disease, hypoxemia, interstitial lung disease, pulmonary edema, pulmonary hypertension, and chronic respiratory failure. Condition outcomes were assessed among adults only as these conditions are extremely rare among children. No. is the number of persons with the given symptom or condition diagnosed 31 to 150 days after SARS-CoV-2 testing. For condition outcomes, we excluded patients who also had a condition in 540–31 days prior to the index test date; total No. = number of persons meeting the inclusion criteria. Therefore, total denominators of condition outcomes vary for each row because of removal of persons with conditions in the baseline period